Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

  title={Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults},
  author={M. Mulligan and K. Lyke and N. Kitchin and J. Absalon and A. Gurtman and S. Lockhart and K. Neuzil and Vanessa N Raabe and Ruth Bailey and Kena A Swanson and P. Li and Kenneth Koury and Warren Kalina and D. Cooper and C. Fontes-Garfias and Pei-Yong Shi and {\"O}. T{\"u}reci and K. Tompkins and E. Walsh and R. Frenck and A. Falsey and P. R. Dormitzer and W. Gruber and U. Şahin and K. Jansen},
  • M. Mulligan, K. Lyke, +22 authors K. Jansen
  • Published 2020
  • Medicine
  • Nature
  • In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 , a pandemic. With rapidly accumulating numbers of cases and deaths reported globally 2 , a vaccine is urgently needed. Here we report the available safety, tolerability and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study ( identifier NCT04368728) among… CONTINUE READING
    44 Citations
    Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
    • 25
    • PDF
    SARS-CoV-2 vaccines in development
    • 30
    • PDF
    RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
    A systematic review of SARS-CoV-2 vaccine candidates
    • 5
    • PDF
    The immunology of SARS-CoV-2 infections and vaccines
    The Current Status of COVID-19 Vaccines
    • 1
    • PDF


    A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
    • 250
    An Infectious cDNA Clone of SARS-CoV-2
    • 71
    • PDF
    Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020
    • 145
    • PDF
    Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
    • 44
    • PDF